Resources Repository
-
Resource PortalWeb Portal, Teaching Resource 2024Millennium Mathematics Project (MMP)
The Millennium Mathematics Project (MMP), a collaboration between the Faculties of Mathematics and Education at the …
The Millennium Mathematics Project (MMP), a collaboration between the Faculties of Mathematics and Education at the University of Cambridge, is a maths education and outreach initiative for ages 3 to 19 and the general public. The focus is on increasing mathematical understanding, confidence and enjoyment, developing problem-solving skills, and promoting creative and imaginative approaches to maths. The project consists of a family of complementary programmes, including the NRICH website, Plus online mathematics magazine, Wild Maths, and…
Probability/Bayes | Environmental Health | Infectious Diseases | Test Performance | Mathematical Models | Decision Analysis | Risk Analysis | Child/Nutrition | Health/Medicine | Science/Technology | Europe | High School | College | Graphics/Visualization | Quantitative Literacy -
Resource PackWeb Portal, Teaching Resource 2017Resource Pack: Valuing Vaccines and GAVI
This resource pack on valuing vaccines and GAVI was curated by the Center for Health …
This resource pack on valuing vaccines and GAVI was curated by the Center for Health Decision Science to showcase existing information and analyses to motivate students, educators and others to pursue new applications of decision science methods to the public health challenge of vaccine preventable illnesses.
Dynamic Transmission | Global Governance | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Costing Methods | Mathematical Models | Calibration/Validation | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Dynamic Transmission | Global Governance | Infectious Diseases | Mathematical Models | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Climate/Environment | Economics/Finance | Health/Medicine | Latin America & Caribbean | Asia & Pacific -
ReviewPublication 2016Decision Support for Infectious Disease Control
This report from RAND reviews decision-support tools, including models and nonmodeling approaches, that are relevant to …
This report from RAND reviews decision-support tools, including models and nonmodeling approaches, that are relevant to infectious disease prevention, detection, and response and aligns these tools with real-world policy questions that the tools can help address. This overview is designed to help modelers and other technical experts understand the questions that policymakers will raise and the decisions they must make. The report also presents policymakers with the capabilities and limitations of the different tools that may…
Dynamic Transmission | Global Governance | Infectious Diseases | Mathematical Models | State-Transition | Microsimulation | Dynamic Simulation | Government/Law | Health/Medicine | Military/Defense | Global -
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
Dynamic Transmission | Global Governance | Infectious Diseases | Health Outcomes | Mathematical Models | State-Transition | Microsimulation | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2020Testing for SARS-CoV-2 Antibodies
Antibody testing can determine previous exposure to SARS-CoV-2 virus. Recently, the UK government has made …
Antibody testing can determine previous exposure to SARS-CoV-2 virus. Recently, the UK government has made antibody testing available to anyone wanting it, even if there is no clinical indication. The purpose of this article is to provide guidance for when to consider antibody testing in individuals with and without symptoms suggestive of current or past SARS-CoV-2 infection. Key points made by the authors include: (1) antibody testing is likely to be most useful 2 weeks…
Probability/Bayes | Infectious Diseases | Test Performance | Technology Assessment | Clinical Care | Health/Medicine -
ToolInteractive 2020COVID-19 Antibody Tests: Calculator for Interpreting Test Results
Antibody testing can determine previous exposure to SARS-CoV-2 virus. This interactive calculator, linked to the article …
Antibody testing can determine previous exposure to SARS-CoV-2 virus. This interactive calculator, linked to the article below* on antibody testing for SARS-CoV-2 virus, allows users to vary the prior probability of infection, the sensitivity of SARS-CoV-2 antibody testing, and the specificity of SARS-CoV-2 antibody testing. Key points made in the article accompanying the interactive include: (1) antibody testing is likely to be most useful 2 weeks after infection, (2) sensitivity and specificity will vary over time and…
Probability/Bayes | Infectious Diseases | Test Performance | Technology Assessment | Clinical Care | Health/Medicine | Science/Technology -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Probability/Bayes | Infectious Diseases | Test Performance | Technology Assessment | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Global | North America -
ArticlePublication 2020Bayes' Theorem, COVID-19, and Screening Tests
This article reviews the implications of increased testing for COVID-19 using reverse transcriptase polymerase chain …
This article reviews the implications of increased testing for COVID-19 using reverse transcriptase polymerase chain reaction (rRT-PCR) through the application of Bayes’ Theorem for three hypothetical, stylized case scenarios. The scenarios involve three patients with a low, moderate, and high pre-test probability of COVID-19 infection. The category of low probability would include "asymptomatic individuals in a presumed low prevalence environment" and might vary from 10 to 20%. The category of moderate probability would include "individuals…
Probability/Bayes | Infectious Diseases | Test Performance | Clinical Care | Health/Medicine